• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Management of cost and utilization of pharmaceuticals in Germany.

作者信息

von der Schulenburg J M

机构信息

University of Hannover, North German Center for Health Services, Gleidingen, Germany.

出版信息

Health Policy. 1997 Sep;41 Suppl:S45-53. doi: 10.1016/s0168-8510(97)00052-3.

DOI:10.1016/s0168-8510(97)00052-3
PMID:10174473
Abstract

The German health care system has had a series of reforms in its pharmaceutical sector, starting in 1988 with the introduction of a reference pricing scheme. A major new reform was introduced in 1993, which established a ceiling for all outpatient pharmaceutical expenditures along with substantial monetary sanctions for breeching that ceiling. A study of that reform, reported here, suggests that outpatient physicians may have responded to this ceiling by increasing their rate of patient referrals to hospitals. New health system reform measures should be constructed with an eye to their overall financial impact on the entire health system.

摘要

相似文献

1
Management of cost and utilization of pharmaceuticals in Germany.
Health Policy. 1997 Sep;41 Suppl:S45-53. doi: 10.1016/s0168-8510(97)00052-3.
2
Cost and utilisation of pharmaceuticals in Sweden.瑞典药品的成本与使用情况
Health Policy. 1997 Sep;41 Suppl:S55-69. doi: 10.1016/s0168-8510(97)00053-5.
3
Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany.利用疾病管理和市场改革应对德国药品预算、价格及报销规定带来的不利经济影响。
Value Health. 2003 Jul-Aug;6 Suppl 1:S20-30. doi: 10.1046/j.1524-4733.6.s1.3.x.
4
Challenges to achieving value in drug spending in a decentralized country: the Spanish case.在一个分权国家实现药品支出价值面临的挑战:以西班牙为例。
Value Health. 2003 Jul-Aug;6 Suppl 1:S52-63. doi: 10.1046/j.1524-4733.6.s1.6.x.
5
Moving beyond the drug budget silo mentality in Europe.超越欧洲药品预算的孤立思维。
Value Health. 2003 Jul-Aug;6 Suppl 1:S74-7. doi: 10.1046/j.1524-4733.6.s1.8.x.
6
The drug budget silo mentality in Europe: an overview.欧洲药品预算的孤立心态:概述
Value Health. 2003 Jul-Aug;6 Suppl 1:S1-9. doi: 10.1046/j.1524-4733.6.s1.1.x.
7
The drug budget silo mentality: the Dutch case.药品预算的筒仓思维:荷兰案例
Value Health. 2003 Jul-Aug;6 Suppl 1:S46-51. doi: 10.1046/j.1524-4733.6.s1.5.x.
8
The drug budget silo mentality: the French case.药品预算的孤立思维:以法国为例。
Value Health. 2003 Jul-Aug;6 Suppl 1:S10-9. doi: 10.1046/j.1524-4733.6.s1.2.x.
9
Comparative experience in home care and pharmaceutical policy.
Health Policy. 1997 Sep;41 Suppl:S1-7. doi: 10.1016/s0168-8510(97)00049-3.
10
[Separate pharmaceutical budgets: skating on thin ice].[独立的药品预算:如履薄冰]
Ned Tijdschr Geneeskd. 2010;154(51-52):A3004.

引用本文的文献

1
Ageing, health status and coverage rate effects on community prescription costs in Ireland.爱尔兰的人口老龄化、健康状况和覆盖范围对社区处方费用的影响。
Eur J Health Econ. 2018 Jun;19(5):687-695. doi: 10.1007/s10198-017-0913-7. Epub 2017 Jun 21.
2
Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.基于参考的定价方案:对药品支出、资源利用和健康结果的影响。
Pharmacoeconomics. 2002;20(9):577-91. doi: 10.2165/00019053-200220090-00002.